Reach Us +44-1647-403003
Tumor Combating Effect Of Lactoferricin B Peptide | 92783
ISSN: 1948-5956

Journal of Cancer Science & Therapy
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Tumor combating effect of Lactoferricin B peptide

8th World Congress on Breast Cancer & Therapies

Ebenezer Chitra, Muhammad Rizdwan Bin Mohd Abd Rahman, Fabian Davamani, Alan Khoo, Munirah Ahmad, Ramkumar Rajendran and Stephen Ambu

International Medical University, MalaysiaInstitute of Medical Research, Malaysia

ScientificTracks Abstracts: J Cancer Sci Ther

DOI: 10.4172/1948-5956-C7-141

Breast cancer is the most common cancer affecting women; survival depends on early diagnosis and treatment. The common choices of treatment are surgery, radiotherapy, hormonal therapy and chemotherapy. Lactoferricin B (Lfcin B) is a 25-mer natural peptide obtained from milk protein lactoferrin and has demonstrated anti-cancer properties. Tumor was induced in the mammary pad of immunocompromized mice by injecting human breast cancer cells, MDA-MB-231 in the breast pad and allowing developing into tumors. The establishment of tumor was confirmed by IVIS in vivo imaging system, which detects the GFP fluorescence from the implanted cells. Once the tumors were palpable, they were injected with lactoferricin B peptide intratumorally (3-5 mg/mouse/day) for 3 subsequent days. The mice were sacrificed 15 days post treatment. The harvested tumors injected with peptide showed a remarkable decrease in size and weight compared to tumors injected with vehicle control PBS. Our studies suggest that Lfcin B can be developed as a potential therapy for breast cancer, especially against drug resistant tumor cells.

Ebenezer Chitra has completed her PhD from National Institute of Immunology, Jawaharlal Nehru University, New Delhi, India. She did her Post-doctoral Fellowship in National Health Research Institutes, Taiwan working on cell signaling in cancer. Currently, she is a Faculty in the School of Health Sciences in International Medical University. Her research interest is in cancer biology.

E-mail: [email protected]


Relevant Topics